Oral function should be measured routinely to determine individual bulbar involvement stages in spinal muscular atrophy (SMA). “Our results underscore the heterogeneity of oral function effort across ...
Add Yahoo as a preferred source to see more of our stories on Google. May 1—At the age of 23, Chloe Caldwell is learning to drive. She had her first lesson in mid-April, but won't be able to get back ...
DUBAI, United Arab Emirates--(BUSINESS WIRE)--Medcare Women & Children Hospital has successfully administered a pioneering intrathecal gene therapy for Spinal Muscular Atrophy (SMA) to Hulus, a ...
Apitegromab met the primary endpoint in the SAPPHIRE trial, showing significant motor function improvement in SMA patients compared to placebo. Scholar Rock plans to submit a biologics license ...
Scholar Rock Holding Corporation focuses on Apitegromab, a selective anti-latent myostatin antibody for Spinal Muscular Atrophy in patients aged 2 and above. The initial FDA BLA submission for ...
A new study describes a base editing method for treating spinal muscular atrophy (SMA). This supports early signs that “single-shot” treatments from clinical trials using genome editing technologies ...
Dubai’s Medcare Hospital Becomes the World’s First to Treat an Adult Spinal Muscular Atrophy (SMA) Patient Outside the US Medcare Royal Speciality Hospital (MRSH) in Dubai has become the world’s first ...
Biogen’s successor to Spinraza (nusinersen) has shown benefit in spinal muscular atrophy (SMA) patients who had suboptimal clinical status despite prior administration of gene therapy. In the Phase Ib ...
For a rare disease, spinal muscular atrophy (SMA) -- a genetic neuromuscular condition that, when left untreated, can cause progressive muscle weakness -- is getting lots of attention from Big Pharma ...
Add Yahoo as a preferred source to see more of our stories on Google. The Food and Drug Administration on Monday approved a new version of Novartis' gene therapy for spinal muscular atrophy, aimed at ...
PHILADELPHIA--(BUSINESS WIRE)--Exegenesis Bio, a rapidly growing global genetic medicines company, is pleased to announce the presentation of clinical efficacy and safety data from its EXG001-307 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results